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ABSTRACT
Tumour cells generally become more susceptible to virus infec-
tion than normal cells due, in part, to a deficient interferon (IFN)-
induced antiviral pathway. One of the key IFN-induced enzymes with
potent antiviral action is the ds-RNA dependent protein kinase PKR,
that once activated blocks protein synthesis, triggers apoptosis and
prevents cell growth. Among viruses, vaccinia virus (VACV) lacking
selected viral genes or armed with cytokines or tumour specific anti-
gens has been used in preclinical and clinical studies as a therapeu-
tic agent against different tumours. Here we showed in a mouse mod-
el of aggressive cancer by subcutaneous inoculation with prostate
TRAMP-C1 cells, that a VACV recombinant expressing low levels of
human PKR (VV-PKR) and lacking thymidine kinase (TK), is capa-
ble of reducing tumour burden when administered by a systemic
route in immunocompetent C57/BL6 mice. In addition, expression of
PKR was found to attenuate the virus, thus ensuring safety. A cata-
litically inactive enzyme PKR with a point mutation (K296R) induced
similar oncolytic activity as the control virus lacking TK. These find-
An. R. Acad. Nac. Farm., 2010, 76 (3): 327-342
327
ARTÍCULO
ings suggest that VACV recombinants expressing PKR are candidate
vectors against cancer cells.
Keywords: Protein kinase PKR; recombinant vaccinia virus; on-
colytic activity; prostate tumours; mouse model.
RESUMEN
Actividad oncolítica del virus vaccinia que expresa la proteína
quinasa PKR inducida por los interferones y dependiente de RNA
bicatenario.
Las células tumorales son generalmente mas susceptibles a la in-
fección viral que las células normales debido, en parte, a tener defi-
ciencias en el sistema de señalización por los interferones (IFN). Uno
de los enzimas clave inducidos por IFN es la proteína quinasa PKR
dependiente de RNA bicatenario, que una vez activada fosforila el fac-
tor de iniciación eIF-2 alfa lo que conlleva a una inhibición generali-
zada en la síntesis de proteínas, inducción de la apoptosis y preven-
ción del crecimiento celular. Como agente terapéutico frente a
distintos tumores se está utilizando en preclínica y clínica el virus vac-
cinia que carece de ciertos genes virales, expresa ciertas citoquinas o
antígenos tumorales. En esta investigación demostramos en un mo-
delo agresivo de cáncer en ratón por inoculación ex vivo de células
tumorales de próstata TRAMP-C1, que se reduce el crecimiento tumo-
ral tras la infección a ratones inmunocompetentes C57/BL6 por vía
sistémica de un virus recombinante de vaccinia que expresa bajos ni-
veles de PKR. Además, la expresión de PKR conduce a la atenuación
del virus en los tejidos. Un mutante catalíticamente inactivo de PKR
produce niveles similares de actividad oncolítica, pero con replicación
viral en tejidos. Estos resultados indican que vectores recombinants
de vaccinia que expresan PKR son candidatos como vectores para lu-
char contra tumores.
Palabras Clave: Proteína quinasa PKR; virus vaccinia recombi-
nante; actividad oncolítica; tumor de próstata; modelo ratón.
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1.  INTRODUCTION
Cancer is a multi-faceted process by which cells are sequentially
transformed, lose cell growth control, develop tumours at specific
sites and cells spread to different tissues leading to metastasis.
Different strategies to fight cancer are used in the clinic, from sur-
gery to chemotherapy, immune-therapy and more recently, although
experimentally, through the use of viral vectors with the ability to de-
stroy tumour cells. This therapeutic strategy uses oncolytic viral vec-
tors with preference for replication in tumour cells, causing cell de-
struction (1). Vaccinia virus has a strong oncolytic effect due to its
fast replication cycle and a high innate tropism to cancer tissue (2).
Tumour targeting can be further improved by deleting vaccinia virus
genes that are necessary for replication in normal cells but not in can-
cer cells. For example, deletions of either thymidine kinase (TK), vac-
cinia virus growth factor (VGF), or both have been shown to reduce
pathogenicity compared to wild-type virus (3, 4). To enhance antitu-
mor potency, oncolytic vaccinia viruses can be armed with therapeu-
tic transgenes, such as immunostimulatory factors or suicide genes.
The clinical data obtained thus far with the oncolytic poxvirus vec-
tors shows that intratumoral injection and replication lead to repro-
ducible delivery of the virus to systemic metastasis through the blood-
stream with tumour necrosis; however, hurdles remain. Neutralizing
response to the virus vector, nature of the inflammatory response re-
quired for tumour regression and limited application to locally ad-
vanced tumours, are among obstacles to be solved. Thus, develop-
ment of poxvirus vectors with improved oncolytic characteristics are
needed.
To search for novel viral vectors with enhanced oncolytic activity,
we have taken advantage of a property of cancer cells, which frequent-
ly lose their ability to produce or respond to interferons (IFN). These
molecules play critical roles in host defence against viral infections,
control of cell growth and immune modulation (5). The poor response
of tumour cells to IFN make these cells more prone to viral infection,
hence forming the basis by which oncolytic viruses are used to de-
stroy tumour cells as they replicate to a better extent in tumour cells
than in normal cells. Among the proteins induced by IFN with antivi-
ral importance is the ds-RNA dependent protein kinase PKR, an en-
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zyme that when activated by dsRNA is authoposphorylated leading to
phosphorylation of the alpha subunit of the eukaryotic initiation fac-
tor eIF-2 (eIF2α) and, in turn, to inhibition of protein synthesis, in-
duction of apoptosis and cell death (for review of PKR see (6)). Since
PKR induction is dependent on sensitivity of the cells to IFN, we rea-
soned that a VACV vector expressing PKR should infect and destroy
better cancer cells than normal cells, as the latter have a fully active
IFN system. Thus, in this investigation we have explored the oncolyt-
ic ability of a VACV recombinant expressing low levels of PKR (re-
ferred to as VV-PKR) in cultured tumour cells and in a mouse mod-
el after subcutaneous inoculation of prostate tumour cells (TRAMP-
C1). The use of a viral recombinant expressing low levels of PKR is
because high levels of expression of PKR prevent virus growth (7, 8).
Our findings showed that VV-PKR replicate in cultured tumour cells,
but when inoculated in subcutaneous TRAMP-C1 tumour-bearing
mice causes reduction of tumour burden in spite of restricted virus
growth.
2.  MATERIALS AND METHODS
2.1.  Cells and viruses
TRAMP-C1 murine prostate cancer cell line obtained from
American Type Culture Collection was maintained in DMEM with 10%
foetal calf serum (FCS) and antibiotics. Cells reaching 95% conflu-
ence were shortly tripsinized, and harvested with serum-containing
medium. The cells were washed and resuspended in serum-free com-
plete medium at concentration of 5 x 106 viable cells in 1 ml. Half-
million TRAMP-C1 cells in 100 μl were implanted subcutaneously into
the right flank. Tumour volume was estimated using the formula: m1
2
x m2 x 0.5236, where m1 and m2 represented the short and long diam-
eter of the tumour, respectively. Tumours were measured using a dig-
ital calliper twice weekly until day 55 post-implantation or until the
tumour burden has met the humane endpoint. Tumours that could
not be measured with calliper but were found to infiltrate surround-
ing tissues at the necropsy were assigned as immeasurable. Tumour-
free status was assigned to mice that at the necropsy have shown lack
of residual tumour tissue at the implantation site.
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The Western Reserve strain of vaccinia virus was used to generate
the recombinant viruses expressing the WT and the human mutant
PKR proteins. The recombinant genes were inserted in the TK locus
of viral genome. PKR expression is regulated by the lac I repressor
gene that is under the control of VACV early-late promoter p7.5. The
mutant PKR, K296R has lost the catalityc activity of PKR due to sub-
stitution of the lysine 296 by arginine. The mutant VACV viruses ex-
pressing PKR (VV-PKR), its inactive mutant form (VV-K296R) and lu-
ciferase (VVLUC) have been previously described (9, 10). Viruses were
grown in monkey BSC-40 cells and purified by sucrose gradients.
TRAMP-C1 cells grown in12-well plates were infected at low 0.01
pfu/cell or high 5 pfu/cell virus multiplicities. Following virus adsorp-
tion for 60 min at 37 ºC, the inoculum was removed and cells incubat-
ed with fresh DMEM containing 2% FCS at 37 ºC in a 5% CO2 atmos-
phere. At different times postinfection, cells were collected by scraping
and used either for Western blot or virus titration. At 24 h postinfec-
tion (hpi), infected cells were lysed in Laemmli buffer, cell extracts frac-
tionated by 12% SDS-PAGE and analyzed by Western blot using rab-
bit polyclonal anti-vaccinia serum, anti-PKR or anti-phospho PKR.
Virus yields were determined by plaque formation at 48 hpi in mon-
key BSC-40 cells after staining with 1% crystal violet in 2% ethanol.
2.2.  Evaluation of virus pathogenicity
Mice C57/BL6, four per group, were inoculated at days 0 and 3 with
a dose of 5x107 pfu per mouse with different viral recombinants,
VVLUC, VV-K296R or VV-PKR, by either intraperitoneal or intranasal
routes. Mice were weighed daily and signs of illness were scored. Virus
was titrated from homogenates of spleen and lung of each mouse at
different days post-infection by a plaque assay in monkey BSC-40 cells.
2.3.  Evaluation of oncolytic activity
Male mice C57/BL6 seven weeks old, 10 animals per group, were
injected by subcutaneous route with 1x106 of TRAMP-C1 of mouse
prostate cancer cells. At the median tumour volume of 75 to 100 mm3
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(30 days post-inoculation), mice were injected by intraperitoneal route
with 5x107 pfu of vaccinia virus VVPKR, VVLUC, VVK296R, or saline
PBS. Virus inoculation by i.p was performed twice in animals with
developed tumours, giving the virus at times 0 and after 3 days.
Tumours were measured every 3-4 days using digital calliper.
3.  RESULTS
3.1.  VACV recombinants with PKR under control of the lac 
I operator/repressor system induced PKR in tumour
prostate cancer cells
We have previously described a VACV recombinant expressing PKR
(VV-PKR) under control of the inducible lac I operator/repressor sys-
tem (9, 11); scheme in Figure 1A). Briefly, when cultured cells are in-
fected with VV-PKR in the presence but not in the absence of IPTG,
PKR is produced at high levels and this leads to its own phosphory-
lation triggered by the viral dsRNA produced during infection from
symmetrical transcription, followed by phosphorylation of eIF-2 al-
pha and in turn, inhibition of protein synthesis, activation of caspas-
es, induction of apoptosis and cell death (6, 12). However, we noted
that when tumour cells TRAMP-C1 are infected with VV-PKR in the
absence of IPTG there low levels of PKR are produced when com-
pared to the infection in the presence of IPTG (Figure 1B). Similar
observation was found when TRAMP-C1 cells were infected with the
mutant form of PKR (K296R), in which case the presence of IPTG
markedly increased the levels of PKR (Figure 1B). As expected, high
levels of PKR produced in the presence of IPTG correlated with phos-
phorylation of eIF-2α, while low levels of PKR in the absence of IPTG
induced lower eIF2α phosphorylation. This was not observed when
the catalitically inactive mutant form of PKR (K296R) was synthe-
sized (Figure 1B). As determined by Western blot with antibodies
against vaccinia proteins, the accumulation of viral proteins was not
impaired in TRAMP-C1 cells infected with VV-PKR in the absence of
IPTG, while it was blocked when IPTG was present (Figure 1C).
Moreover, virus yields were similar in cells infected with the control
virus VV-LUC, a virus expressing luciferase marker in the TK locus,
as in cells infected with VV-PKR in the absence of IPTG (Figure 1D),
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Figure 1.  Characteristics of vaccinia virus recombiant vectors expressing PKR.
A. Scheme of the recombinant vaccinia virus vectors. The Western Reserve strain of
vaccinia virus was used to generate the recombinant viruses expressing the human
wild type (WT) and the mutant PKR proteins. The recombinant genes were inserted
in the TK locus of viral genome. PKR expression is regulated by the lac I repressor
gene that is under the control of VV early-late promoter p7.5. The mutant PKR, K296R
has lost the catalityc activity of PKR due to substitution of the lysine 296 by argi-
nine. B. TRAMP-C1 cells were infected with 5 pfu/cell of vaccinia virus recombinants
VV-PKR and VV-K296R in presence or absence of the inductor IPTG (5 mM). The
PKR expression and PKR catalytic activity was analyzed at different time post-infec-
tion using specific antibodies against total PKR and the phosphorylated form of
eIF2α. C. TRAMP-C1 cells were infected with 5 pfu/cell of vaccinia virus recombi-
nants VVLUC and VV-PKR in presence or absence of the inductor IPTG (5 mM). The
vaccinia virus proteins at 24 hpi were detected using specific polyclonal antibody to
VACV proteins. D. TRAMP-C1 cells were infected with 0.001 pfu/cell of vaccinia virus
recombinants VVLUC and VVPKR in presence or absence of the inductor IPTG 
(5 mM). Virus yields were measured at 0 and 48 hpi after titration by plaque assay
in monkey BSC-40 cells.
while in the presence of IPTG virus yields were inhibited. Induction
of PKR in TRAMP-C1 cells infected with VV-PKR could be due to leak-
iness of the promoter or as a result of the viral infection.
The above findings establish that VV-PKR can be used as a vector
to produce low levels of PKR in tumour TRAMP-C1 cells.
3.2.  Attenuation of VV-PKR in infected mice
To evaluate whether low level expression of PKR could be biolog-
ically active leading to virus attenuation, we performed pathogenici-
ty studies in mice, by measuring survival, virus titration in tissues and
humoral immune responses to the virus. Thus C57/BL6 mice, 4 ani-
mals per group, were injected either by intraperitoneal (i.p.) or in-
tranasal (i.n.) routes with 5x107 plaque forming units (pfu) of either
VV-LUC, VV-PKR and VV-PKR(K296R) or with a solution of PBS.
Several signs of viral illness, like ruffled fur, rigidity, lack of activity
and mortality were evaluated with time of infection. As shown in
Figure 2A, i.n. inoculation of VV-LUC results in severe illness and the
animals had to be sacrificed by day 6 due to the loss of 30% of their
body weight, while animals that received VV-PKR recovered the
weight loss by day 7 after viral infection. Animals inoculated with VV-
PKR(K296R) behaved similarly as VV-LUC (not shown). The signs of
illness correlated well with virus abundance in lung tissues, with about
5 log reduction at day 3 in mice inoculated i.n. with VV-PKR in com-
parison with VV-Luc (Figure 2A, lower panel). When animals were in-
oculated with the different viruses by i.p. routes, VV-Luc or VV-
PKR(K296R) induced weight loss while infection with VV-PKR did
not (Figure 2B); this correlated with lower virus titers in the spleen
compared with animals administered with VV-LUC or VV-PKR
(K296R) (Figure 2B, lower panel). To provide further support for re-
duced replication of VV-PKR in mice, we evaluated by ELISA the an-
tibody response against the viral recombinants at 30 days after i.p. in-
oculation with the different viruses. As expected, VV-PKR induced
lower antibodies against VACV antigens than either VV-LUC or VV-
PKR(K296R) (Figure 3). The findings of Figures 2 and 3 establish that
VV-PKR is attenuated in mice when inoculated by i.n. or i.p. routes
and induces low levels of antibodies against the virus vector.
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3.3.  Systemic inoculation of VV-PKR in mice with transplantable
prostate cancer cells reduces tumour burden
Next we wanted to define if VV-PKR could be used as an oncolyt-
ic vector. Thus, C57/BL6 mice were inoculated by subcutaneous route
with TRAMP-C1 prostate tumour cells and when the tumour median
volume reached 75 to 100 mm3, 10 mice per group were injected by
i.p. route with 5x107 pfu of different VACV vectors: VV-LUC, VV-PKR
and its mutant VV-PKR(K296R), or control PBS. Virus was inoculat-
ed twice with the same dose, three days apart. Tumour size was
recorded every 3-4 days using a digital caliper. As shown in Figure 4,
the tumour size was reduced in mice inoculated with the three viral
Figure 2. VV-PKR shows reduced pathogenicity in comparison to VVLUC and
VV-K296R in C57/BL6 mice. A. Mice C57/BL6, four per group, were inoculated with
5x107 pfu per mouse of VVLUC or VV-PKR by intranasal route. Mice were weighed
daily. Virus was titrated in lungs at third day post-infection. B. Mice C57/BL6, four
per group, were inoculated with 5x107 pfu per mouse with VVLUC, VV-K296R, VV-
PKR or PBS by intraperitoneal route at days 0 and 3. Mice were weighed daily. Virus
was titrated in spleen at third and fifth days post-infection. Mean values titers are
shown.
vectors, although there was a trend of slightly higher tumour reduc-
tion in mice inoculated with the viral vectors expressing PKR. The
virus titers at the tumour site remain elevated in animals inoculated
with VV-Luc compared to animals inoculated with VV-PKR. At day 5
after the administration of two doses of virus by i.p. inoculation, the
mean virus titers in 3 mice were 3.9x106 pfu/gr tissue in the tumours
of VV-LUC compared to less then 102 in VV-PKR.
Previously, it has been shown that virus lacking TK improves the
oncolytic activity of VACV (3). Our results showing that VV-PKR ex-
hibits reduced replication in tissues compared to either VV-LUC or
VV-PKR(K296R), together with the fact that tumours were reduced
similarly by VV-PKR as for the other two vectors, indicate that 
VV-PKR is a self-limited replication vector with oncolytic activity.
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Figure 3.  Antibody response against different VACV recombinants. Detection of
antibodies against vaccinia virus (by ELISA) in serum obtained 23 days post-infec-
tion from mice, four per group, inoculated i.p. twice (days 0 and 3) with 5x107 pfu
per mouse of each recombinant viruses VVLUC, VV-PKR, VV-K296R or PBS. 96-well
plates were fixed with 1 μg/well of soluble cell extract from VACV-infected BSC-40
cells. A single serum dilution of 1:400 was used for all samples. Absorbance of serum
dilution from each mouse is shown.
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4.  DISCUSSION
Oncolytic vaccinia viruses have demonstrated tumour specificity,
high levels of transgene expression, and anti-tumour effect (13-15).
PKR is an interferon-induced kinase that is able to induce apoptosis
through eIF2α and NFkB modulation, and have a discussed tumour
suppressor activity. PKR is also involved in the pathways of several tu-
mour suppressors such as p53, IRF1, ARF and MDA7 (6). To define
the contribution of PKR as an oncolytic agent, we have evaluated the
antitumoral activity of a recombinant vaccinia virus expressing PKR
inserted in the TK locus, in immunocompetent C57/BL6 mice bearing
subcutaneous tumours produced by the prostate cancer cell line
Figure 4.  Diminished TRAMP-C1 tumour growth in C57/BL6 mice treated with
recombinant vaccinia viruses VV-PKR, VV-K296R and VVLUC. A. Male mice
C57/BL6 seven weeks old, 10 per group, were injected by subcutaneous route with
1x107 of TRAMP-C1 mouse prostate cancer cells. At the median tumour volume of
75 to 100 mm3 (30 days post-inoculation), mice were injected by intraperitoneal route
with 5x107 pfu of vaccinia virus VVPKR, VVLUC, VVK296R, or saline PBS on days
0 and 3. Tumours were measured every 3-4 days using digital caliper. B. Virus titers
in transplantable tumours. Shown are the mean virus titers in pfu/gr of tumour tis-
sue obtained by surgery 5 days after the second dose of virus was administered by
i.p. route.
TRAMP-C1. We found that VV-PKR replicates efficiently in prostate tu-
mour TRAMP-C1 cultured cells while it expresses low levels of PKR.
However, inoculation of VV-PKR in mice by either i.n. or i.p. routes
results in reduced virus replication in tissues and animals recovered
from viral infection. Significantly, the establishment of an aggressive
tumour in mice by subcutaneous inoculation of TRAMP-C1 cells was
markedly reduced following systemic inoculation with VV-PKR. This
reduction in tumour burden was similar to that induced by viral vec-
tors lacking TK, similar to VV-LUC or the catalitically inactive mutant
VV-PKR(K296R). Since VV-PKR also lacks TK but has a reduced ca-
pacity to propagate in tissues than either VV-LUC or VV-PKR(K296R),
the fact that the vector inhibits the tumour growth similarly as the two
other vectors, suggest that the contribution of PKR is important to re-
strict tumour growth. This could be mediated by activation of PKR in
infected tumour cells leading to apoptosis and cell death, while nei-
ther VV-LUC or VV-PKR(K296R) are able to induce apoptosis (16, 17).
However, we could not detect virus propagation in most of the animals
inoculated with VV-PKR at the tumour site, while virus was easily
found in tumours from animals inoculated by i.p. with VV-LUC or VV-
K296R. This indicates that factors other than virus replication in tu-
mour cells are responsible for PKR-induced tumour reduction. The re-
duced virus propagation of VV-PKR will have the added advantage that
antibody responses against the vector will be minimized. In fact, we
observed that in mice inoculated i.p. with VV-PKR the levels of anti-
bodies produced against the virus vector are about 5-fold lower than
those triggered by either VV-LUC or VV-PKR (296R). This character-
istic made it possible the administration in vivo of repetitive doses of
VV-PKR at the tumour site or systemically as shown here, while a ful-
ly replicating VACV vector triggering strong antibody response against
itself will be more restricted after additional doses of the vector are in-
oculated.
Why PKR may be an advantage as an inhibitor of tumour growth?
Considering its mode of action, PKR has been shown to act in concert
with major inflammatory kinases and directly interact with a critical
insulin signalling component, suggesting PKR as a core component of
a putative metabolic inflammasome that consist of major elements in
inflammatory signalling and insulin action, which can represent a cen-
tral mechanism for the integration of pathogen response and innate
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immunity (6, 18). Based on previous observations on the mode of ac-
tion of PKR and our findings here in mice, we suggest that VV-PKR
might exert its antitumour action not by direct virus replication at the
tumour site but through the triggering of innate immune pathways. In
fact, PKR has been shown to activate multiple signalling pathways (6).
By microarray analyses in human tumour cells infected with VV-PKR
we have shown that expression of PKR triggered the induction of 111
genes, of which 97 were upregulated, among those the ATF-3 transcrip-
tion factor involved in stress-induced B-cell apoptosis, which might
also contribute to the antitumor activity of PKR (19). Recently, it has
been shown that induction of the tumour suppressor p53 by DNA-dam-
aging stress results in significant increase in the expression of PKR
and in turn in PKR-associated biological functions like a translation-
al block and apoptosis, thus contributing to tumour suppression (20).
Undoubtedly, induction of PKR in the context of a tumour cell togeth-
er with its activation by the dsRNA provided from the vector VV-PKR
has the advantage that it provides the signals that lead rapidly to in-
nate immune cell activation, like the inflammatory complex, and in
turn to tumour growth control.
The oncolytic VACV vectors that have been developed to date are
either lacking one or several viral genes or expressing exogenous prod-
ucts that improve the killing ability of the virus vector. Among delet-
ed viral genes: TK (thymidine kinase) with produces a nucleotide pool
for replication of the viral genomes, vaccinia growth factor (VGF) that
activates the epidermal growth factor receptor, and a variety of im-
munosuppressive proteins, like B18R which binds and sequester type
I interferons (4). Improvements in the killing activity of the vector are
a variety of molecules, like vectors expressing cytokines, anti-angio-
genic agents, agents that disrupt the extracellular matrix to improve
viral spread, and prodrug-converting enzymes (21-23). Phase I and II
clinical trials are ongoing with some of the oncolytic VACV vectors.
The most advanced vector in the clinic is the one that had inactivat-
ed both TK and VGF and also expresses GM-CSF (21). While all of
the oncolytic VACV vectors developed had full replication capacity,
which makes them more vulnerable to attack by CTLs and antibod-
ies, the vector VV-PKR described here has more restricted replication,
but importantly triggers low antibody response against itself and re-
duces tumour burden.
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Overall, our studies provided evidence for a new class of an on-
colytic VACV vector inducing low levels of PKR in tumour cells and
lacking TK, as a product to selectively destroy tumour cells, not by di-
rect killing but probably by the triggering of innate immune mecha-
nisms, like the inflammasome.
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